Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

Journal of Neuroinflammation

Volumn 15, Issue 1, 2018, Pages

  García, Concepción ^a,b,c   Gómez Cañas, María ^a,b,c   Burgaz, Sonia ^a,b,c   Palomares, Belén ^d,e,f   Gómez Gálvez, Yolanda ^a,i   Palomo Garo, Cristina ^a,b,c   Campo, Sara ^a   Ferrer Hernández, Joel ^a   Pavicic, Carolina ^g   Navarrete, Carmen ^h   Luz Bellido, M ^h   García Arencibia, Moisés ^a,b,c,j   Ruth Pazos, M ^a,b,c,k   Muñoz, Eduardo ^d,e,f   Fernández Ruiz, Javier ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^d Maimonides Institute for Research in Biomedicine of Cordoba   (Spain)

^e UNIVERSITY OF CÓRDOBA   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g Innohealth Group   (Spain)

^h Vivacell Biotechnology España   (Spain)

ⁱ KEELE UNIVERSITY   (United Kingdom)

^j UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^k HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

more..

Author keywords

Cannabinoids; Inflammation; LPS; Microglial activation; Parkinson's disease; PPAR receptors; VCE 003.2

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; CANNABIGEROL; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUINONE DERIVATIVE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VCE 003 2; CANNABINOID; NEUROPROTECTIVE AGENT; VCE-003;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING SITE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BV-2 CELL LINE; CELL DEATH; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; EXPERIMENTAL PARKINSONISM; GLIOSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KKU-M213 CELL LINE; MALE; MOLECULAR DOCKING; MTT ASSAY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; RAT; SUBSTANTIA NIGRA; UPREGULATION; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECT; INFLAMMATION; METABOLISM; MICROGLIA; MOUSE; NERVE CELL; PARKINSONISM; PHYSIOLOGY;

ANIMALS; BINDING SITES; CANNABINOIDS; CELL LINE; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PPAR GAMMA; QUINONES;

EID: 85040741073     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-018-1060-5     Document Type: Article

References (56)

1. Lim S, Chun Y, Lee JS, Lee SJ. Neuroinflammation in synucleinopathies. Brain Pathol. 2016;26:404-9.
2. Fernández-Ruiz J, Romero J, Ramos JA. Endocannabinoids and neurodegenerative disorders: Parkinson's disease, Huntington's chorea, Alzheimer's disease, and others. Handb Exp Pharmacol. 2015;231:233-59.
3. Chiurchiù V, Leuti A, Maccarrone M. Cannabinoid signaling and neuroinflammatory diseases: a melting pot for the regulation of brain immune responses. J NeuroImmune Pharmacol. 2015;10:268-80.
4. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernández E, et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci. 2009;29:2177-86.
5. Chung YC, Bok E, Huh SH, Park JY, Yoon SH, Kim SR, et al. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol. 2011;187:6508-17.
6. Gómez-Gálvez Y, Palomo-Garo C, Fernández-Ruiz J, García C. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:200-8.
7. 9 -THCV in animal models of Parkinson's disease. Br J Pharmacol. 2011;163:1495-506.
8. García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007;1134:162-70.
9. 2 receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. Exp Neurol. 2015;269:133-41.
10. 2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine. Neurobiol Aging. 2012;33:421 e1-e16.
11. O'Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology. 2010;215:611-6.
12. Fidaleo M, Fanelli F, Ceru MP, Moreno S. Neuroprotective properties of peroxisome proliferator-activated receptor-α (PPARα) and its lipid ligands. Curr Med Chem. 2014;21:2803-21.
13. Agarwal S, Yadav A, Chaturvedi RK. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochem Biophys Res Commun. 2017;483:1166-77.
14. Carta AR, Simuni T. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease. Expert Opin Investig Drugs. 2015;24:219-27.
15. Pistis M, Melis M. From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem. 2010;17:1450-67.
16. Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013;75:323-33.
17. Granja AG, Carrillo-Salinas F, Pagani A, Gómez-Cañas M, Negri R, Navarrete C, et al. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J NeuroImmune Pharmacol. 2012;7:1002-16.
18. Carrillo-Salinas FJ, Navarrete C, Mecha M, Feliú A, Collado JA, Cantarero I, et al. A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis. PLoS One. 2014;9:e94733.
19. Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, et al. VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. Sci Rep. 2016;6:29789.
20. Hughes TS, Giri PK, de Vera IM, Marciano DP, Kuruvilla DS, Shin Y, et al. An alternate binding site for PPARγ ligands. Nat Commun. 2014;5:3571.
21. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis. 2005;19:96-107.
22. Gómez-Cañas M, Morales P, García-Toscano L, Navarrete C, Muñoz E, Jagerovic N, et al. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol Res. 2016;110:205-15.
23. Chiang MC, Cheng YC, Chen HM, Liang YJ, Yen CH. Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway. Mitochondrion. 2014;14:7-17.
24. Hunter RL, Cheng B, Choi DY, Liu M, Liu S, Cass WA, et al. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res. 2009;87:1913-21.
25. Burton JD, Goldenberg DM, Blumenthal RD. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res. 2008;2008:494161.
26. Palkovits M, Brownstein J. Maps and guide to microdissection of the rat brain. Elsevier, 1988.
27. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785-91.
28. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455-61.
29. Wolf LK. New software and websites for the chemical enterprise. Chem Eng News. 2009;87:31.
30. Baugh EH, Lyskov S, Weitzner BD, Gray JJ. Real-time PyMOL visualization for Rosetta and PyRosetta. PLoS One. 2011;6:e21931.
31. Liberato MV, Nascimento AS, Ayers SD, Lin JZ, Cvoro A, Silveira RL, et al. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists. PLoS One. 2012;7:e36297.
32. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515-27.
33. Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P. Pharmacological manipulation of peroxisome proliferator activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp Neurol. 2012;235:528-38.
34. Zhou M, Wu R, Dong W, Jacob A, Wang P. Endotoxin downregulates peroxisome proliferator-activated receptor-γ via the increase in TNF-α release. Am J Phys Regul Integr Comp Phys. 2008;294:R84-92.
35. Corsi L, Dongmo BM, Avallone R. Supplementation of omega 3 fatty acids improves oxidative stress in activated BV2 microglial cell line. Int J Food Sci Nutr. 2015;66:293-9.
36. Zizzo G, Cohen PL. The PPAR-γ antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-γ in human macrophage polarization. Inflamm (Lond). 2015;12:36.
37. Seargent JM, Yates EA, Gill JH. GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. Br J Pharmacol. 2004;143:933-7.
38. Hughes TS, Chalmers MJ, Novick S, Kuruvilla DS, Chang MR, Kamenecka TM, et al. Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism. Structure. 2012;20:139-50.
39. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37:510-8.
40. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 2005;57:168-75.
41. Gao X, Hu X, Qian L, Yang S, Zhang W, Zhang D, et al. Formyl-methionyl-leucyl-phenylalanine-induced dopaminergic neurotoxicity via microglial activation: a mediator between peripheral infection and neurodegeneration? Environ Health Perspect. 2008;116:593-8.
42. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8:382-97.
43. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol. 2005;58:963-7.
44. Fernández-Ruiz J, Moro MA, Martínez-Orgado J. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics. 2015;12:793-806.
45. Laganà AS, Vitale SG, Nigro A, Sofo V, Salmeri FM, Rossetti P, et al. Pleiotropic actions of peroxisome proliferator-activated receptors (PPARs) in dysregulated metabolic homeostasis, inflammation and cancer: current evidence and future perspectives. Int J Mol Sci. 2016;17:E999.
46. Croasdell A, Duffney PF, Kim N, Lacy SH, Sime PJ, Phipps RP. PPARγ and the innate immune system mediate the resolution of inflammation. PPAR Res. 2015;2015:549691.
47. Aleshin S, Strokin M, Sergeeva M, Reiser G. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: review and novel hypotheses. Neurochem Int. 2013;63:322-30.
48. Hall MG, Quignodon L, Desvergne B. Peroxisome proliferator-activated receptor β/δ in the brain: facts and hypothesis. PPAR Res. 2008;2008:780452.
49. Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta. 2007;1771:1031-45.
50. Arimoto T, Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis. 2003;12:35-45.
51. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 1999;5:1403-9.
52. Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci. 2000;16:724-39.
53. Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, et al. Structural basis for the activation of PPARγ by oxidized fatty acids. Nat Struct Mol Biol. 2008;15:924-31.
54. Oh YT, Lee JY, Lee J, Lee JH, Kim JE, Ha J et al. Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NFΚB activation in BV2 murine microglial cells. Neurosci Lett 2010; 474: 148-153.
55. Necela BM, Su W, Thompson EA. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-ΚB in macrophages. Immunology. 2008;125:344-58.
56. Waku T, Shiraki T, Oyama T, Maebara K, Nakamori R, Morikawa K. The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites. EMBO J. 2010;29:3395-407.